Cognitive Research

DSIP (Delta Sleep Inducing Peptide)

6.1/10

BioHarmony verdict

Worth trying

DSIP (Delta Sleep-Inducing Peptide) is a naturally-occurring nonapeptide whose famous name oversells it. Independent double-blind sleep studies found the effect weak, per Bes 1992 and Monti 1987, and almost all the positive data come from one researcher.

Read full report

What is DSIP (Delta Sleep Inducing Peptide)?

DSIP, short for Delta Sleep-Inducing Peptide, is a naturally-occurring nonapeptide, a chain of nine amino acids your body actually makes. It was first isolated back in 1977 from the cerebral venous blood of rabbits during hypnogenic brain stimulation, per Schoenenberger 1977. When researchers injected it into rabbit brains, it raised delta (slow-wave) EEG activity, the deep-sleep brain rhythm. That is exactly where the name comes from, and that is also where the trouble starts.

From the BioHarmony report, reviewed 2026-09-08.

How it is thought to work

Poorly defined; no isolated receptor and no agreed sleep mechanism

Safety watch-outs

  • Injection-site redness, swelling, warmth, or pus (possible contamination from unverified grey-market product): stop and seek care.
  • Any fever, chills, or systemic reaction after injection (possible endotoxin or contaminant exposure): stop immediately.
  • Using DSIP alongside opioids, sedatives, or alcohol given the proposed opioid-receptor interaction: do not combine without medical…
  • Relying on DSIP as a primary insomnia treatment in place of validated tools: the controlled evidence does not support it.

Full risk profile in the BioHarmony report.

Dosing as published

No approved-label or study protocol is recorded for DSIP (Delta Sleep Inducing Peptide) yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (3)

Attributed viewpoints, separate from primary research.

Trust & sourcing

US approvalNot FDA approved
CompoundingWithdrawn from Category 2 nomination; eligibility is not established
Last checked2026-07-13
Next review2026-10-11

FDA identifies immunogenicity and impurity concerns for compounded emideltide (DSIP) and says route-specific safety information is insufficient.

Primary sources

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.